General Practice Doctors in Huntington Beach, CA Accepting Medicare

7 General Practice doctors found. Showing 1 - 7

Dr. Charles William Jackson, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 17122 Beach Blvd, Suite 102, Huntington Beach, CA 92647 Phone: 714-847-6545    Fax: 714-847-6547

David Stanley Poder, D.O. General Practice Medicare: Not Enrolled in Medicare Practice Location: 6289 Pacific Pointe Dr, Huntington Beach, CA 92648 Phone: 714-849-1826    Fax: 714-374-7438

Barry M. Schwartz, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 17822 Beach Blvd Ste 100, Huntington Beach, CA 92647 Phone: 714-841-1040    Fax: 714-841-1031

Dr. Kazi Rezai, D.O. General Practice Medicare: Accepting Medicare Assignments Practice Location: 18672 Florida St, Suite 302-b, Huntington Beach, CA 92648 Phone: 714-375-0691

Arnold J Brender, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 17742 Beach Blvd, Ste 215, Huntington Beach, CA 92647 Phone: 714-848-1655    Fax: 714-847-4348

Dr. Scott Douglass Ewing, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 20001 Beach Blvd, Huntington Beach, CA 92648 Phone: 949-945-4255    Fax: 714-849-1464

Brian W. Capeloto, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 9042 Garfield Ave Ste 206, Huntington Beach, CA 92646 Phone: 714-729-4156

News Archive

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.

Psychologists have gained insight into how people judge their personal health risks

The findings suggest that people aren't horribly off the mark as long as they do not rely on media reports and stick to what's happened to people they know.

New SARS-CoV-2 modeling suggests virus will remain a threat until the end of 2022

Researchers attempt to predict future transmission rates by identifying multiple scenarios that could occur over the next year.

Machine learning system may offer warnings about negative side effects of drug-drug interactions

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ damage and even death.

PAREXEL implements fMRI technology in early phase CNS drug development

PAREXEL International, a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units.

Read more Medical News

› Verified 7 days ago